By Cole Bunn, Senior Research Analyst, LSN
Orphan diseases present a unique opportunity for an investor as there are several advantages from a regulatory standpoint given the shorter development timeline and exclusivity possibility as well as the ability to truly impact patient’s lives that have no treatment options. On the flipside, they have challenges primarily due to the size of the patient population and usually require a somewhat unique business model and marketing strategy to be a viable opportunity.
In our first and largest RESI conference of 2017, held for the third time at the Marines Memorial Club and Hotel during the JP Morgan healthcare week, a varied group of investors explore some of these challenges and opportunities with funding and commercializing rare disease drugs and share their firsthand experience in this space.
Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:
- Nick Simon, Managing Director, Clarus Ventures
- Ruchita Sinha, Sr. Director of Investments, Sanofi-Genzyme Bioventures
- Bram Vanparys, Director, Merck Ventures
- Theirry Laugel, Managing Partner, Kurma Partners
Next Phase Newsletter 
Leave a comment